Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Roxadustat (FG-4592), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with nondialysis CKD. The 145 p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical journal of the American Society of Nephrology 2016-06, Vol.11 (6), p.982-991
Hauptverfasser:	Provenzano, Robert, Besarab, Anatole, Sun, Chao H, Diamond, Susan A, Durham, John H, Cangiano, Jose L, Aiello, Joseph R, Novak, James E, Lee, Tyson, Leong, Robert, Roberts, Brian K, Saikali, Khalil G, Hemmerich, Stefan, Szczech, Lynda A, Yu, Kin-Hung Peony, Neff, Thomas B
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Aged, 80 and over Anemia - blood Anemia - drug therapy Anemia - etiology C-Reactive Protein - metabolism Cholesterol - blood Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Female Glycine - administration & dosage Glycine - adverse effects Glycine - analogs & derivatives Glycine - therapeutic use Hemoglobins - metabolism Hepcidins - blood Humans Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors Isoquinolines - administration & dosage Isoquinolines - adverse effects Isoquinolines - therapeutic use Male Middle Aged Original Renal Insufficiency, Chronic - complications
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!